As of September 30, 2026, China National Medicines Corporation Ltd. Class A carries a market capitalization of 19.69B, placing it among publicly traded companies globally. Its enterprise value stands at 13.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 19.69B |
| Enterprise Value | 13.77B |
China National Medicines Corporation Ltd. Class A's next confirmed earnings release is scheduled for March 25, 2027.
| Earnings Date | 3/25/2027 |
As of September 30, 2026, China National Medicines Corporation Ltd. Class A has 754.50M shares outstanding.
| Shares Outstanding | 754.50M |
As of September 30, 2026, China National Medicines Corporation Ltd. Class A trades at a trailing price-to-earnings ratio of 9.94. The price-to-sales ratio is 0.37, and the price-to-book ratio stands at 1.01.
| PE Ratio | 9.94 |
| PS Ratio | 0.37 |
| PB Ratio | 1.01 |
| P/TBV Ratio | 1.04 |
As of September 30, 2026, China National Medicines Corporation Ltd. Class A trades at an EV/EBITDA multiple of 5.26 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.26 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 13.77B versus a market cap of 19.69B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 0.26 |
| EV / EBITDA | 5.26 |
| EV / EBIT | 5.26 |
As of September 30, 2026, China National Medicines Corporation Ltd. Class A maintains a current ratio of 2.19, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.38, indicating elevated leverage, while an interest coverage ratio of 119.07 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.19 |
| Quick Ratio | 0.56 |
| Debt / Equity | 2.38 |
| Debt / EBITDA | 0.19 |
| Interest Coverage | 119.07 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately 17.76M in revenue per employee across its workforce of 3,024.00, a quick read on workforce productivity versus industry peers.
| Revenue Per Employee | 17.76M |
| Employee Count | 3,024.00 |
Over the twelve months ended September 30, 2026, China National Medicines Corporation Ltd. Class A recorded 551.09M in income tax expense. That works out to an effective tax rate of 21.40, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.57B, leaving 1.98B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 551.09M |
| Effective Tax Rate | 21.40 |
As of the close on November 17, 2026, China National Medicines Corporation Ltd. Class A's stock has declined approximately 3.38% over the past 52 weeks. The 50-day moving average sits at 27.25, while the 200-day moving average is 27.93.
| 52-Week Price Change | -3.38% |
| 50-Day Moving Average | 27.25 |
| 200-Day Moving Average | 27.93 |
Over the twelve months ended September 30, 2026, China National Medicines Corporation Ltd. Class A generated 53.69B in revenue and converted that into 1.98B in net income, yielding earnings per share of 2.68. EBITDA reached 2.62B, while operating income came in at 2.14B.
| Revenue | 53.69B |
| Gross Profit | 3.53B |
| Operating Income | 2.14B |
| Pretax Income | 2.57B |
| Net Income | 1.98B |
| EBITDA | 2.62B |
| EBIT | 2.62B |
| Earnings Per Share (EPS) | 2.68 |
As of September 30, 2026, China National Medicines Corporation Ltd. Class A holds 8.16B in cash and equivalents against 504.08M in total debt, resulting in a net debt position of -7.92B. Total book value stands at 19.41B, with working capital of 17.37B providing operational flexibility.
| Cash & Cash Equivalents | 8.16B |
| Total Debt | 504.08M |
| Net Debt | -7.92B |
| Equity (Book Value) | 19.41B |
| Book Value Per Share | 25.72 |
| Working Capital | 17.37B |
These figures cover the twelve months ended September 30, 2026.
| Capital Expenditures | -69.26M |
Over the twelve months ended September 30, 2026, China National Medicines Corporation Ltd. Class A posted a gross margin of 6.57, reflecting its pricing power and cost economics. The operating margin of 3.98 and net profit margin of 3.69 provide insight into operational efficiency.
| Gross Margin | 6.57 |
| Operating Margin | 3.98 |
| Pretax Margin | 4.80 |
| Profit Margin | 3.69 |
| EBITDA Margin | 4.88 |
Over the twelve months ended September 30, 2026, China National Medicines Corporation Ltd. Class A paid dividends of 0.82 per share. The dividend payout ratio of 30.02 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 6.39, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to China National Medicines Corporation Ltd. Class A shareholders.
| Dividend Per Share | 0.82 |
| Payout Ratio | 30.02 |
| Shareholder Yield | 6.39 |
China National Medicines Corporation Ltd. Class A's most recent stock split took place on June 3, 2009 with a 1:2 split ratio.
| Last Split Date | 6/3/2009 |
| Split Ratio | 1:2 |
As of September 30, 2026, China National Medicines Corporation Ltd. Class A has an Altman Z-Score of 3.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.60 |
Already premium?